StockData

Arcturus Therapeutics vs Scynexis

ARCT and SCYX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARCT and SCYX compare

Arcturus Therapeutics is the larger company, worth 8.2 times as much as Scynexis ($236M against $29.0M).

Scynexis grew revenue faster over the last twelve months (490% versus −76.0% for Arcturus Therapeutics).

Scynexis keeps more of each dollar of sales as profit, with a net margin of −53.3% compared with −318% at Arcturus Therapeutics.

Scynexis scores higher on the StockData Score (13 against 9 for Arcturus Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARCTSCYX
Size and price
Market cap$236M$29.0M
Share price$8.31$2.91
Change, 1 year6.9%−38.4%
Change, 5 years−79.2%−95.1%
Beta (5Y)1.971.56
Employees11118
StockData Score
Total score913 (better)
Valuation score23 (better)
Growth score02 (better)
Performance score23 (better)
Health score55
Dividend score00
Valuation
P/S8.0×1.5× (better)
P/B1.4×0.4× (better)
FCF yield−30.8%–
Fair value$8.82$10.10
Margin of safety5.8%71.2% (better)
Growth
Revenue growth (TTM)−76.0%490% (better)
Revenue growth, 5Y average53.8%–
Profitability
Operating margin−348%−118% (better)
Net margin−318%−53.3% (better)
FCF margin−248%–
Return on equity−46.3%−18.4% (better)
Return on invested capital−1084%–
Financial health
Debt / equity0.000.00
Current ratio5.889.65 (better)
Altman Z-score−1.33 (better)−5.22
Piotroski F-score25 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions87.9%51.7%
Held by insiders8.1%24.8%
Short interest, % of float20.7%6.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.